Filing Flows › Labcorp Holdings (LH) › Guidance & outlook
Labcorp Holdings (LH) guidance and outlook
Labcorp Holdings (LH) raised its guidance on Oct 28, 2026: Revenue +14.5% for FY2026; Revenue +50 bps for FY2026; EPS $18.30–$18.70 for FY2026; Revenue +5.4% for FY2026. Labcorp Holdings' 10-Q filed Oct 30, 2026 makes 12 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | +14.5% | raised |
| Revenue | FY2026 | +50 bps | raised |
| EPS | FY2026 | $18.30–$18.70 | raised |
| Revenue | FY2026 | +5.4% | raised |
From the earnings release filed Oct 28, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Oct 30, 2026
- 19. inability to achieve the expected benefits and synergies of newly acquired businesses, including due to items not discovered in the due diligence process, and the impact on the Company’s cash position, levels of indebtedness, and stock price;
- 34. challenges, deficiencies, or higher-than-anticipated costs in implementing, integrating, or operating the Company’s new ERP system across broader areas of the Company could disrupt the Company’s business operations, including its supply chain and procurement processes, result in data errors, impair its ability to process transactions, or reduce cash flows or liquidity, including as a result of increased…
- 38. failure to maintain the expected capital structure for the Company, including failure to maintain the Company’s investment grade rating, or failure to comply with the leverage ratio or other financial covenants under its debt agreements;
- 42. failure to achieve expected efficiencies, benefits, and savings in connection with the Company’s business process improvement initiatives;
- 45. risks associated with the impacts and expected benefits and costs of the completed Spin-off of the Company’s former clinical development and commercialization services business, Fortrea, including but not limited to factors that could adversely affect the Company’s ability to realize the expected benefits of the Spin-off or the failure of the Spin-off to qualify as a tax-free transaction for U.S. federal…
- The potential impacts described above represent the Company’s assessment at this time, and the Company will continue to evaluate the impact of the OBBBA on its business and operations as the legislation’s provisions continue to become effective through 2028.
- Capital expenditures for the nine months ended September 30, 2026, were 3.6% of Revenues, primarily in connection with projects to support growth in the Company’s core businesses, facility expansion and updates, implement advanced technology, and further acquisition integration activities.
- The Company was in compliance with all covenants at September 30, 2026, and expects continued compliance with its existing covenants and leverage ratios for the next 12 months.
- The Company has a noncancelable contract with a vendor to purchase supplies inventory pursuant to which the Company is obligated to make expected total future minimum payments of $111.5, including $4.8 for the remainder of 2026, $32.7 in 2027, and $74.0 in 2028.
- Based on current and projected levels of cash flows from operations, coupled with availability under its revolving credit facility and the AR Facility, the Company believes it has sufficient liquidity to meet both its anticipated short-term and long-term cash needs for the next 12 months and the reasonably foreseeable future; however, the Company continually reassesses its liquidity position in light of market…
- In addition, the Company expects to refinance its $600.0 3.60% senior notes due 2027, which mature on September 1, 2027.
- In the current interest rate environment, the Company expects that new or refinanced debt will bear interest at rates higher than that of the debt being replaced, which will also increase interest expense.
Labcorp Holdings' latest quarter
Labcorp Holdings, Q3 2026: revenue $3.8B (+7% year over year), operating margin 10.6%, net earnings $263M, operating cash flow $564M. The chart follows the revenue to costs, profit and cash.
Questions
Did Labcorp Holdings raise or lower its guidance?
Labcorp Holdings (LH) raised its guidance on Oct 28, 2026: Revenue +14.5% for FY2026; Revenue +50 bps for FY2026; EPS $18.30–$18.70 for FY2026; Revenue +5.4% for FY2026.
What does Labcorp Holdings expect?
19. inability to achieve the expected benefits and synergies of newly acquired businesses, including due to items not discovered in the due diligence process, and the impact on the Company’s cash position, levels of indebtedness, and stock price; 34. challenges, deficiencies, or higher-than-anticipated costs in implementing, integrating, or operating the Company’s new ERP system across broader areas of the Company could disrupt the Company’s business operations, including its supply chain and procurement processes, result in data errors, impair its ability to process transactions, or reduce ca
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.